ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "methotrexate (MTX)"

  • Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium

    Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis

    Ryan Funk1 and Mara Becker 2, 1University of Kansas, Leawood, Kansas, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill

    Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
  • Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting

    Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    Naonori Tsuda1, Shigeko Inokuma 2, Kenichi Hiraga 3, Yoshinori Masui 3 and Toshikazu Kano 3, 1Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, 2Chiba Central Medical Center, Ichikawa, Chiba, Japan, 3Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan

    Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
  • Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting

    Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

    Iván de Jesús Hernández-Galarza 1, Rita Pineda-Sic1, Marielva Castro-Gonzalez 1, Diana Elsa Flores-Alvarado 1, Octavio Ilizaliturri-Guerra 1, Rodolfo Uriarte-Botello 1 and Dionicio Galarza-Delgado 1, 1Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
  • Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting

    Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

    Katie Bechman1, Anuoluwapo Oke 2, Mark Yates 3, Sam Norton 3, Elaine Denderson 4, Andrew Cope 5 and James Galloway 2, 1Kings College London, London, England, United Kingdom, 2Kings College London, London, United Kingdom, 3Kings College London, London, 4MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, 5Academic Rheumatology, King's College London, London, United Kingdom

    Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
  • Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting

    Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA

    Alexis Ogdie1, Ervant Maksabedian 2, Bradley Stolshek 2, Yomei Shaw 3 and Kaleb Michaud 4, 1University of Pennsylvania, Philadelphia, PA, 2Amgen Inc., Thousand Oaks, CA, 3FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA).  One…
  • Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting

    The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis

    Laura Coates1, Joseph Merola 2, Philip Mease 3, Alexis Ogdie 4, Dafna Gladman 5, Vibeke Strand 6, Leonieke van Mens 7, Lyrica Liu 8, Priscilla K Yen 8, David Collier 8, Gregory Kricorian 8, James Chung 8 and Philip Helliwell 9, 1University of Oxford, Oxford, United Kingdom, 2Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 3Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 4Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 6Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 7University of Amsterdam, Amsterdam, Netherlands, 8Amgen Inc., Thousand Oaks, CA, 9University of Leeds, Leeds, United Kingdom

    Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
  • Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting

    Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease

    Renuka Nayak1, Margaret Alexander 1, Kye Stapleton-Grey 2, Carles Ubeda 3, Jose Scher 4 and Peter Turnbaugh 1, 1UCSF, San Francisco, 2Carnegie Mellon, Pittsburg, 3Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, 4Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY

    Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
  • Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting

    Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial

    stéphanie Ferrero 1, Ruth Wittoek 2, Edem Allado 3, Coralie Cruzel 4, Véronique Breuil 1, Liana Euller Ziegler 5, Damien louille 6, Christian Roux7 and Joel Kremer 8, 1University of Nice, nice, France, 2Ghent University Hospital, Gent University, Gent, Belgium, 3Centre Hospitalier Universitaire de Nancy, Nancy, France, 4Université Cote d'Azur, nice, France, 5PUPH CHU NICE, nice, France, 6Université Cote d'Azur, Nancy, France, 7Université Cote d'Azur, Nice, 8Albany Medical College, Albany, NY

    Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
  • Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting

    Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)

    Daniel Solomon1, Robert Glynn 2, Elizabeth Karlson 3, Fengxin Lu 3, Cassandra Corrigan 3, Joshua Colls 3, Chang Xu 3, Jean MacFadyen 3, Medha Barbhaiya 4, Nancy Berliner 3, Paul Dellaripa 3, Brendan Everett 3, Sara Hammond 3, Meredith Murray 3, Deepak Rao 3, Susan Ritter 5, Anna Rutherford 5, Jeffrey Sparks 3, Jacklyn Stratton 5, Dong Suh 3, Sara K. Tedeschi 6, Kathleen Vanni 3, Nina Paynter 5 and Paul Ridker 5, 1Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 2Harvard Medical School - Boston, MA, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Brigham and Women's Hospital, Boston, 6Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA

    Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
  • Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting

    miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients

    Rohan Machhar1, Justine (Yang) Ye 2, Remy Pollock 1 and Dafna Gladman 3, 1Krembil Research Institute, University Health Network, Toronto, Canada, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
  • Abstract Number: 2067 • 2019 ACR/ARP Annual Meeting

    Comparison of Medication New User Definitions in Multi-Specialty EMR Data

    Jeffrey Curtis1, Lang Chen 1, Narender Annapureddy 2, Cassie Clinton 1, Megan Clowse 3, Millie Long 4, W. Benjamin Nowell 5, Jim Oates 6, Rennie Rhee 7, Siddarth Singh 8, Fenglong Xie 9 and Timothy Beukelman 10, 1University of Alabama at Birmingham, Birmingham, AL, 2Vanderbilt University, Nashville, TN, 3Duke University, Durham, 4University of North Carolina Chapel Hill, Chapel Hill, NC, 5Global Healthy Living Foundation, Upper Nyack, NY, 6Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, 7University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, 8University California, San Diego, San Diego, 9University of Alabama at Birmingham, Birmingham, 10University of Alabama Birmingham, Birmingham, AL

    Background/Purpose: New user designs are typically preferred in pharmacoepidemiology to avoid bias. The optimal implementation of a new user design in electronic medical record (EMR)…
  • Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting

    Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

    W. Benjamin Nowell1, Elaine Karis 2, Kelly Gavigan 1, Laura Stradford 1, Scott Stryker 3, Shilpa Venkatachalam 1, Gregory Kricorian 3 and Jeffrey Curtis 4, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Amgen Inc, Thousand Oaks, CA, 3Amgen Inc., Thousand Oaks, CA, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
  • Abstract Number: 369 • 2019 ACR/ARP Annual Meeting

    Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review

    Esteban Rubio1, Alejandro Muñoz 1 and Núria Casamira 2, 1Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, 2Medical Department, Gebro Pharma S.A., Barcelona, Spain

    Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases.  Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
  • Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting

    Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture

    Suguru Honda1, Ryoko Sakai 2, Masako Majima 1, Naoko Konda 1, Hideto Takada 1, Kazuhiko Yamamoto 3, Tsutomu Takeuchi 4 and Masayoshi Harigai 1, 1Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Riken Center for Integrative Medical Sciences, Kanagawa, Japan, 4Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
  • Abstract Number: 384 • 2019 ACR/ARP Annual Meeting

    Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease

    Connie Lam 1, Stephen Bloom 2 and Alberta Hoi3, 1School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 2Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, 3School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia

    Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…
  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.